Skip to content
buyWeak

Clay Thorp bought $14k of CLSD

director at Clearside Biomedical, Inc.. 15,000 shares at an average of $0.92, traded Feb 24, 2025, filed Feb 24, 2025.

Conviction score
18
Value
$14k
15,000 shares
Holdings after
176,141
+9% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $14k at market
    0
  • Relative to holdings
    Holdings up 9%
    +3
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001415889-25-005325, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 24, 2025POpen-market purchase
Common Stock
+15,000$0.92$14k176,141Feb 24, 2025

Related signals

Other insiders at Clearside Biomedical, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
31Weak
CLSDbuy
Clearside Biomedical, Inc.
Ngai Hang Victor Chong
Chief Medical Officer
$37k
36,500 shares
+57%
25Weak
CLSDbuy
Clearside Biomedical, Inc.
Ngai Hang Victor Chong
Chief Medical Officer
$25k
23,500 shares
+59%
25Weak
CLSDbuy
Clearside Biomedical, Inc.
Benjamin R Yerxa
director
$10k
7,813 shares
+77%
34Weak
CLSDbuy
Clearside Biomedical, Inc.
Anthony S Gibney
director
$130k
100,000 shares
-
30Weak
CLSDbuy
Clearside Biomedical, Inc.
Ngai Hang Victor Chong
CHIEF MEDICAL OFFICER
$48k
30,000 shares
-
24Weak
CLSDbuy
Clearside Biomedical, Inc.
Bradford T Whitmore
owner
$600k
444,444 shares
+11%
30Weak
CLSDsell 2
Clearside Biomedical, Inc.
Charles A. Deignan
Chief Financial Officer
$17k
12,900 shares
-3%
33Weak
CLSDsell 2
Clearside Biomedical, Inc.
George M Lasezkay
CEO
$23k
18,000 shares
-4%
12Weak
CLSDbuy
Clearside Biomedical, Inc.
Bradford T Whitmore
owner
$100k
135,778 shares
+3%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Clay Thorp bought $14k of CLSD | InsiderTell